Cytosorbents (NASDAQ:CTSO) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Monday morning,Benzinga reports. They currently have a $10.00 target price on the medical research company’s stock.

Other research analysts have also recently issued reports about the stock. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. StockNews.com initiated coverage on shares of Cytosorbents in a research note on Monday. They issued a “hold” rating for the company. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Up 12.0 %

Cytosorbents stock opened at $1.05 on Monday. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.59. The stock’s fifty day simple moving average is $0.92 and its 200-day simple moving average is $1.03. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $57.41 million, a P/E ratio of -2.92 and a beta of 0.58.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Sargent Investment Group LLC increased its holdings in Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. bought a new stake in shares of Cytosorbents in the third quarter valued at approximately $51,000. Finally, Geode Capital Management LLC lifted its stake in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.